Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2219-2226

  de Jonge, Maja J A ^a   Punt, Cornelis J A ^a   Hans Gelderblom, A ^a   Loos, Walter J ^a   van Beurden, Vera ^a   Planting, André S Th ^a   van der Burg, Maria E L ^a   van Maanen, Lydia W G M ^a   Dallaire, Brian K ^a   Verweij, Jaap ^a   Theo Wagener, D J ^a   Sparreboom, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE; MACROGOL;

ADULT; AGED; ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0033034388     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2219     Document Type: Article

References (33)

1. Giovanella BC, Stehlin JS, Wall ME, et al: DNA Topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
2. Pantazis P, Kozielski AJ, Vardeman DM, et al: Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol Res 5:273-281, 1993
3. Giovanella BC, Stehlin JS, Hinz HR, et al: Studies on time/dose intensity in treatment of human cancer xenografts with camptothecin analogues. Proc Am Assoc Cancer Res 35:455, 1994 (abstr 2713)
4. Pantazis P, Hinz HR, Mendoza JT, et al: Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res 52:3980-3987, 1992
5. De Souza PL, Cooper MR, Imondi AR, et al: 9-Aminocamptothecin: A topoisomerase I inhibitor with preclinical activity in prostate cancer. Clin Cancer Res 3:287-294, 1997
6. Supko JG, Malspeis L: Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res 53:3062-3069, 1993
7. Supko JG, Plowman J, Dykes DJ, et al: Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC603071) antitumor activity in mice and its plasma pharmacokinetics. Proc Am Assoc Cancer Res 33:432, 1992 (abstr 2578)
8. Rubin E, Wood V, Bharti A, et al: A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin Cancer Res 1:269-276, 1995
9. Dahut W, Harold N, Takimoto C, et al: Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J Clin Oncol 14:1236-1244, 1996
10. Takimoto CH, Dahut W, Marino MT, et al: Pharmacokinetics and pharmacodynamics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients. J Clin Oncol 15:1492-1501, 1997
11. Siu LL, Oza AM, Eisenhauer EA, et al: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16:1122-1130, 1998
12. Eder JP Jr, Supko JG, Lynch T, et al: Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion. Clin Cancer Res 4:317-324, 1998
13. Potmesil M, Liebes L, Drygas J, et al: Antitumor efficacy and pharmacokinetics of intragastric (IG) 20-(S)-camptothecin (CAM) and analogs in human cancer xenograft model. Proc Am Soc Clin Oncol 14:489, 1995 (abstr 1598)
14. Mani S, Iyer L, Janisch L, et al: Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol 42:84-87, 1998
15. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
16. Loos WJ, Sparreboom A, Verweij J, et al: Determination of the lactone and lactone plus carboxylate forms of 9-aminocamptothecin in human plasma by sensitive high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 694:435-441, 1997 (abstr)
17. Sparreboom A, de Jonge MJA, Punt CJA, et al: Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors. Clin Cancer Res 4:1915-1919, 1998
18. Phillips PC, Janss A, Kaufmann SH, et al: Topoisomerase I Inhibitor schedule dependent activity and determinants of cytotoxicity in human brain tumor cell lines. Proc Am Assoc Cancer Res 35:363, 1994 (abstr 2161)
19. Burris HA, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor against human tumor colony forming units in vitro. J Natl Cancer Inst 23:1816-1820, 1992
20. Houghton PJ, Chesire PJ, Myer L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxy-camptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31:229-239, 1991
21. Houghton PJ, Chesire PJ, Hallman JD, et al: Efficacy of topoisomerase inhibitor topotecan and irinotecan administered at lower dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
22. Gerrits CJH, de Jonge MJA, Schellens JHM, et al: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962, 1997
23. Schellens JHM, Creemers GJ, Beijnen JH, et al: Bioavailability and pharmacokinetic of oral topotecan: A new topoisomerase I inhibitor. Br J Cancer 73:1268-1271, 1996
24. Gerrits CJH, Schellens JHM, Creemers, GJ, et al: The bioavailability of oral GI 147211 (GG211), a new topoisomerase-I inhibitor. Br J Cancer 76:946-951, 1997
25. Stewart CF, Zamboni WC, Crom WR, et al: Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice. Cancer Chemother Pharmacol 40:259-265, 1997
26. Gerrits CJH, Burris H, Schellens JHM, et al: Oral topotecan given once or twice daily for ten days: A phase I and pharmacology study in adult patients with solid tumors. Clin Cancer Res 4:1153-1158, 1998
27. Creemers GJ, Gerrits CJH, Eckardt JR, et al: Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors. J Clin Oncol 15:1087-1093, 1997
28. Verschraegen CF, Natelson EA, Giovanella BC, et al: A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 9:36-44, 1998
29. Creemers GJ, Gerrits CJH, Schellens JHM, et al: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14:2540-2545, 1996
30. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
31. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096, 1997
32. Stehlin JS, Natelson EA, Hinz HR, et al: Phase I clinical trial and pharmacokinetic results with oral administration of 20-S-camptothecin, in Potmesil M, Pinedo H (eds): Camptothecins: New Anticancer Agents. Boca Raton, FL, CRC Press, 1995, pp 59-65
33. Sparreboom A, de Jonge MJA, Punt CJA, et al: Limited-sampling models for 9-aminocamptothecin pharmacokinetics after oral drug administration. 10th EORTC NCI 10:60, 1998 (abstr 228)